MaxCyte, Inc. Result of Special Meeting (3656E)

TIDMMXCT TIDMTTM

RNS Number : 3656E

MaxCyte, Inc.

06 July 2021

Result of Special Meeting

GAITHERSBURG, MD, 06 July 2021 - MaxCyte, Inc., (LSE: MXCT, MXCN), a leading provider of platform technologies for cell engineering, announces that at the Special Meeting held earlier today in respect of the Company's proposed US-registered public offering of shares of Common Stock and dual-listing of the Common Stock on Nasdaq (the "Proposed Offering"), each of the resolutions as set out in the notice of Special Meeting was duly passed, with the sole exception of Resolution 5, which is not a requirement for the Proposed Offering to proceed.

The Special Meeting was convened following the Company's announcement on 14 May 2021, that it had confidentially submitted a draft registration statement on Form S-1 to the SEC relating to a proposed dual-listing and public offering of shares of Common Stock on Nasdaq. The exact timing of the Proposed Offering as well as the number of and the price of the shares of Common Stock to be offered and sold in the Proposed Offering have not yet been determined. The Proposed Offering is subject to the Securities and Exchange Commission satisfactorily completing its review of the Company's registration statement related thereto in addition to market and other conditions. There is no assurance that the Proposed Offering will be completed, nor is there certainty as to the timing of the Proposed Offering.

As a result of the outcome of the Special Meeting, should the Proposed Offering proceed, MaxCyte's Directors intend to maintain the admission of the shares of Common Stock to trading on AIM alongside listing of the shares of Common Stock on Nasdaq. Accordingly, Stockholders will continue to be able to deal in shares of Common Stock on AIM and, in due course, may also deal in shares of Common Stock on Nasdaq. The Company will continue to be subject to the AIM Rules for Companies.

The Company intends to provide further details in due course in an announcement to be made via a Regulatory Information Service as to how, subject to completion of the Proposed Offering, Stockholders will be able to move shares of Common Stock between the UK and the US.

This press release is being made pursuant to, and in accordance with Rule 135 under the Securities Act of 1933, as amended (the "Securities Act"). This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. MaxCyte's existing customer base ranges from large biopharmaceutical companies - including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic centers focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted pre-clinical and clinical licences to academic and industry customers covering an estimated 140 programmes, of which an estimated 100 are for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US.

MaxCyte Contacts:

 
 
  MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Amanda Murphy, Chief Financial Officer              +1 301-944-1660 
Nominated Adviser and Joint Corporate Broker 
 Panmure Gordon 
 Emma Earl / Freddy Crossley 
 Corporate Broking 
 Rupert Dearden                                       +44 (0)20 7886 2500 
Joint Corporate Broker 
 Numis Securities Limited 
 James Black / Duncan Monteith / Matthew O'Dowd       +44 (0)20 7260 1000 
Joint Corporate Broker 
 Stifel Nicolaus Europe Limited 
 Healthcare Investment Banking 
 Nicholas Moore / Ben Maddison / Samira Essebiyea 
 Corporate Broking 
 Nick Adams                                           +44 (0) 20 7710 7600 
Financial PR Adviser 
 Consilium Strategic Communications                   +44 (0)203 709 5700 
 Mary-Jane Elliott                                    maxcyte@consilium-comms.com 
 Chris Welsh

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMUPUGWMUPGGQQ

(END) Dow Jones Newswires

July 06, 2021 12:36 ET (16:36 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024